...
....
Pharmaceutical
Biotechnology

> See specialized channels
Medical Devices & Diagnostics
> See specialized channels
Industrial
Biotechnology
> See specialized channels


  Join us

  Follow us on Twitter   Join our LinkedIn Group   Our Blog

Biotech News App
Provides access to the latest biotech press releases ...more

Android_Logo App Store RIM_Logo_small

Media Partnership:
Want to have your RSS feed integrated on our website? Contact us
RSS Feeds RSS Feeds
JoomlaWatch Stats 1.2.9 by Matej Koval
For Editors
Sign up for press releases
For Companies
Sign up for our newsletter
Back to PRESS RELEASES - 

GATC Biotech and LifeCodexx Develop Diagnostic Test for Early Detection of Preeclampsia

| Print |
Thursday, 12 May 2011 14:00 (UTC + 2)
GATC_Biotech_logo2 Livecodexx_Logo

Project is funded with 500,000 Euros from the BMBF

Constance, Germany, May 12, 2011 / B3C newswire / – Preeclampsia is a hypertensive disorder of the mother during pregnancy. It is among the leading causes of death of mother and unborn child and occurs in approximately two to five percent of all pregnancies in Germany. Early detection is critical and improves the prognosis for the further course of the pregnancy.

On the basis of next generation sequencing technologies GATC Biotech and LifeCodexx will develop a human genetic diagnostic test that will allow the detection of cell-free fetal DNA as an important early marker. The test would allow a reliable risk assessment before symptoms appear. The project is supported by grants from the KMU Innovation Program of the Federal Ministry for Research and Education with 500,000 Euros over the next two years.

"Currently there is no reliable method to predict preeclampsia. This new genetic test will therefore provide additional assurance early in pregnancy," said Dr. Wera Hofmann, Medical Director of LifeCodexx AG.

"We will immediately investigate the new PacBio RS technology for use in the test protocol. This sequencing system of the Third Generation can analyze single molecules in real-time within minutes. Costs and duration of the diagnostic test could be drastically reduced,” added Peter Pohl, CEO of GATC Biotech and chairman of LifeCodexx.

“We are pleased to have a second diagnostic test in our development pipeline, in addition to the non-invasive prenatal diagnostic test for the determination of trisomy 21. It is another step forward towards our goal to become a leader in the field of Next Generation Molecular Diagnostics,” said Dr. Michael Lutz, CEO of LifeCodexx AG.


Contact:

LifeCodexx AG
Dr. Michael Lutz
Chief Executive Officer
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
+49 (0) 7531 81 60 15

GATC Biotech AG
Elke Decker
Director Strategic Marketing & Corporate Communications
This e-mail address is being protected from spambots. You need JavaScript enabled to view it